See more : Wakita & Co.,LTD. (8125.T) Income Statement Analysis – Financial Results
Complete financial analysis of iBio, Inc. (IBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iBio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Vitro, S.A.B. de C.V. (VITROA.MX) Income Statement Analysis – Financial Results
- Ayalon Insurance Company Ltd (AYAL.TA) Income Statement Analysis – Financial Results
- Sydinvest Europa Ligevægt & Value KL (SYIEULVADKK.CO) Income Statement Analysis – Financial Results
- Benefit One Inc. (BNTOF) Income Statement Analysis – Financial Results
- TM Technology, Inc. (5468.TWO) Income Statement Analysis – Financial Results
iBio, Inc. (IBIO)
About iBio, Inc.
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 225.00K | 0.00 | 2.38M | 2.37M | 1.64M | 2.02M | 444.00K | 394.00K | 948.00K | 1.85M | 205.00K | 1.01M | 1.28M | 520.08K | 0.00 | 1.18M | 987.06K | 896.27K |
| Cost of Revenue | 0.00 | 1.11M | 216.00K | 1.46M | 703.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.84K | 485.13K | 445.72K |
| Gross Profit | 225.00K | -1.11M | 2.17M | 909.00K | 935.00K | 2.02M | 444.00K | 394.00K | 948.00K | 1.85M | 205.00K | 1.01M | 1.28M | 520.08K | 0.00 | 675.77K | 501.93K | 450.55K |
| Gross Profit Ratio | 100.00% | 0.00% | 90.94% | 38.34% | 57.08% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 57.43% | 50.85% | 50.27% |
| Research & Development | 5.19M | 10.33M | 17.73M | 9.99M | 3.21M | 5.47M | 3.99M | 4.12M | 3.16M | 3.50M | -150.00K | 3.43M | 4.98M | 3.08M | 2.52M | 797.40K | 550.00K | 673.23K |
| General & Administrative | 11.67M | 19.02M | 34.13M | 22.03M | 12.43M | 12.33M | 10.69M | 10.55M | 7.69M | 5.02M | 4.20M | 4.24M | 5.62M | 7.09M | 2.07M | 1.80M | 1.82M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.67M | 19.02M | 34.13M | 22.03M | 12.43M | 12.33M | 10.69M | 10.55M | 7.69M | 5.02M | 4.20M | 4.24M | 5.62M | 7.09M | 2.07M | 1.80M | 1.82M | 1.44M |
| Other Expenses | 0.00 | 0.00 | 13.00K | 12.00K | 10.00K | 16.00K | 19.00K | 25.00K | 21.00K | 32.00K | 45.00K | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M |
| Operating Expenses | 16.86M | 29.34M | 51.86M | 32.02M | 15.64M | 17.81M | 14.67M | 14.67M | 10.84M | 8.52M | 4.05M | 7.67M | 10.60M | 10.17M | 4.59M | 2.60M | 2.37M | 2.12M |
| Cost & Expenses | 16.86M | 29.34M | 52.07M | 33.48M | 15.64M | 17.81M | 14.67M | 14.67M | 10.84M | 8.52M | 4.05M | 7.67M | 10.60M | 10.17M | 4.59M | 3.10M | 2.85M | 2.56M |
| Interest Income | 363.00K | 130.00K | 178.00K | 140.00K | 15.00K | 75.00K | 15.00K | 39.00K | 22.00K | 9.00K | 130.00K | 9.00K | 11.67K | 12.62K | 12.73K | 20.42K | 0.00 | 0.00 |
| Interest Expense | 172.00K | 0.00 | 1.41M | 2.45M | 2.47M | 1.90M | 1.92M | 1.93M | 807.00K | 0.00 | 122.00K | 90.00K | 62.85K | 50.50K | 13.11K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.25M | 1.11M | 3.79M | 2.41M | 2.24M | 1.75M | 1.71M | 1.68M | 940.00K | 363.00K | 361.00K | 338.00K | 329.71K | 376.81K | 337.03K | 283.95K | 245.27K | 322.04K |
| EBITDA | -14.02M | -28.12M | -25.72M | -18.35M | -11.74M | -13.95M | -12.48M | -12.53M | -8.91M | -6.30M | -3.31M | -5.86M | -5.35M | -9.28M | -5.73M | -1.62M | -1.62M | -1.34M |
| EBITDA Ratio | -6,231.56% | 0.00% | -1,918.09% | -1,305.74% | -716.54% | -691.18% | -2,811.71% | -3,181.22% | -939.87% | -340.52% | -1,611.71% | -624.63% | -994.23% | -1,312.61% | 0.00% | -139.57% | -164.16% | -149.86% |
| Operating Income | -16.63M | -29.31M | -49.69M | -31.11M | -14.00M | -15.79M | -14.23M | -14.27M | -9.89M | -6.67M | -3.84M | -6.67M | -9.33M | -9.65M | -4.59M | -1.93M | -1.87M | -1.67M |
| Operating Income Ratio | -7,392.89% | 0.00% | -2,085.19% | -1,312.15% | -854.88% | -782.36% | -3,204.28% | -3,622.84% | -1,043.57% | -360.13% | -1,873.17% | -662.07% | -730.19% | -1,856.25% | 0.00% | -163.71% | -189.00% | -185.79% |
| Total Other Income/Expenses | 1.19M | 0.00 | 184.00K | 7.90M | -2.44M | -1.81M | -1.88M | -1.87M | -764.00K | 41.00K | 174.00K | 469.00K | 3.65M | -2.49M | -1.49M | 20.42K | 0.00 | 0.00 |
| Income Before Tax | -15.44M | -29.31M | -50.30M | -23.21M | -16.44M | -17.60M | -16.11M | -16.14M | -10.66M | -6.63M | -3.67M | -6.20M | -5.62M | -12.10M | -6.08M | -1.91M | -1.87M | -1.67M |
| Income Before Tax Ratio | -6,863.56% | 0.00% | -2,110.95% | -979.04% | -1,003.91% | -872.00% | -3,627.93% | -4,096.19% | -1,124.16% | -357.91% | -1,788.29% | -615.49% | -440.34% | -2,327.44% | 0.00% | -161.97% | -189.00% | -185.79% |
| Income Tax Expense | 0.00 | -1.64M | 701.00K | 46.00K | 2.47M | -4.00K | 34.00K | 347.00K | -65.00K | -9.00K | 45.00K | 120.00K | -3.65M | 2.49M | 2.40K | 1.53K | 3.71K | 851.00 |
| Net Income | -24.91M | -29.31M | -51.01M | -23.26M | -18.92M | -17.59M | -16.11M | -14.53M | -9.76M | -6.63M | -3.67M | -6.20M | -5.68M | -12.14M | -6.08M | -1.91M | -1.87M | -1.67M |
| Net Income Ratio | -11,069.78% | 0.00% | -2,140.37% | -980.98% | -1,154.76% | -871.80% | -3,627.25% | -3,688.32% | -1,029.96% | -357.91% | -1,788.29% | -615.49% | -444.35% | -2,334.73% | 0.00% | -162.10% | -189.38% | -185.88% |
| EPS | -6.50 | -47.87 | -116.97 | -59.45 | -80.53 | -70.50 | -37.87 | -40.77 | -30.15 | -23.17 | -14.56 | -31.38 | -35.92 | -98.02 | -55.65 | -23.53 | -19.92 | -17.76 |
| EPS Diluted | -6.50 | -47.87 | -116.97 | -59.45 | -80.53 | -70.50 | -37.87 | -40.77 | -30.15 | -23.17 | -14.56 | -31.38 | -35.92 | -98.02 | -55.65 | -23.53 | -19.92 | -17.76 |
| Weighted Avg Shares Out | 3.83M | 612.25K | 436.05K | 391.25K | 234.90K | 249.54K | 425.24K | 356.44K | 323.89K | 285.98K | 251.87K | 197.52K | 158.02K | 123.88K | 109.21K | 81.06K | 93.83K | 93.83K |
| Weighted Avg Shares Out (Dil) | 3.83M | 612.25K | 436.05K | 391.25K | 234.90K | 249.54K | 425.24K | 356.44K | 323.89K | 285.98K | 251.87K | 197.52K | 158.02K | 123.88K | 109.21K | 81.06K | 93.83K | 93.83K |
iBio Stock Is Not Likely To Move Higher Given Its Huge Dilution
8 Biotech Penny Stocks for Investors to Watch
iBio to Participate in the 33rd Annual Roth Conference
7 Penny Stocks In a Make-or-Break Year
Hold iBio Shares as Q2 Highlights Strong Product Catalog
Why Bausch Health, Oncolytics Biotech, And More Are Moving Today
iBio, Inc. (IBIO) CEO Tom Isett on Q2 2021 Results - Earnings Call Transcript
iBio Reports Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update
7 Penny Stocks That Look Far Too Risky to Bet On
iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021
Source: https://incomestatements.info
Category: Stock Reports